NCT00057473
Completed
Phase 2
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
ConditionsNeoplasms
Overview
- Phase
- Phase 2
- Intervention
- carboplatin + irinotecan
- Conditions
- Neoplasms
- Sponsor
- Bristol-Myers Squibb
- Locations
- 1
- Primary Endpoint
- estimate response rate
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Arm A
Intervention: carboplatin + irinotecan
Arm B
Intervention: irinotecan
Outcomes
Primary Outcomes
estimate response rate
Secondary Outcomes
- evaluate safety
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerSmall Cell Lung CancerNCT00695292SCRI Development Innovations, LLC37
Completed
Phase 2
Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00469898Vanderbilt-Ingram Cancer Center50
Completed
Phase 2
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerCarcinoma, Small Cell LungLung CancerNCT00308529SCRI Development Innovations, LLC55
Completed
Phase 2
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerCarcinoma, Small Cell LungNCT00294931SCRI Development Innovations, LLC50
Completed
Phase 2
Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer PatientsOvarian NeoplasmsNCT01124435Catholic University of the Sacred Heart45